Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years clinical trials

Explore recruiting symptomatic nonerosive gerd in paediatric subjects aged 2 to 11 years clinical trials.

Also recruiting in Europe

Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years trials by city

Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Toronto Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Vancouver Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Montreal Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Calgary Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Edmonton Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Ottawa Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Winnipeg Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Quebec City Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Hamilton Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Kitchener Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in London Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Halifax Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in New York Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Los Angeles Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Chicago Symptomatic Nonerosive Gerd In Paediatric Subjects Aged 2 To 11 Years in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease